Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
•
Relapsing polychondritis
•
Aortitis
In a young patient with relapsing polychondritis and aortitis which has led to severe aortic valve regurgitation, is there any preference for a mechanical versus bioprosthetic valve replacement?
Related Questions
How would you approach the workup of a female patient who has recurrent sinusitis with polyps (biopsy showed active and chronic inflammation) and myocarditis, but negative ANCA and normal eosinophil counts?
What biologic or conventional/synthetic DMARD would you use as a steroid sparing agent in a patient with GCA and a history of diverticulitis?
How long do you continue rituximab in patients with ANCA associated vasculitis who have achieved remission?
What is your approach to treating IgA nephropathy in patients who also have IgA vasculitis?
In patients with suspected relapsing polychondritis, can pain, redness, and swelling occur only with sustained pressure on the ears or nose, rather than presenting spontaneously?
How soon after starting treatment for Takayasu arteritis do you decide on the need for any vascular interventions to manage chronic damage?
How would you approach a patient with high CRP, rising liver enzymes and new biopsy proven liver granulomas 6 months after starting methotrexate and Rituximab therapy for ANCA vasculitis?
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
How would you approach failure of maintenance therapy (Azathioprine) for PR3 positive, c-ANCA positive, pulmonary–renal vasculitis previously induced with cyclophosphamide, with a history of anaphylaxis to rituximab?
How would you manage a patient with Takayasu arteritis controlled on TNFi who develops erythema nodosum that is only partially responsive to NSAIDs?
